Shots:
- Bayer has reported P-III (OCEANIC-STROKE) trial data assessing asundexian (50mg, QD, PO) vs PBO, both in combination with antiplatelet therapy, in pts (n=12,300) for prevention of ischemic stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack
- Trial met its primary efficacy & safety EPs, with a significant reduction in the risk of ischemic stroke, plus no increase in the risk of ISTH major bleeding was observed
- Additionally, Bayer will work with global health authorities to prepare marketing authorization submissions & plans to share the results at a future scientific meeting
Ref: Bayer | Image: Bayer | Press Release
Related News:- Bayer’s Hyrnuo (Sevabertinib) Gains the US FDA Accelerated Approval for Advanced HER2-mutant NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
